Johnson & Johnson: EPS just beats consensus
(CercleFinance.com) - Johnson & Johnson has posted Q4 2019 adjusted net profit that is down 6.
4% at 5.03 billion dollars, i.e. 1.88 dollar per share, while the street expected one cent less.
The healthcare group's revenues increased by 1.7% to over 20.7 billion dollars, up 2.6% in operational terms (i.e. excluding FX factors). When also adjusted for changes in the group's consolidation scope, revenues increased by 3.4%.
With FY adjusted EPS of 8.68 dollars, against a target range of between 8.84 dollars and 8.89 dollars, provided three months ago, Johnson & Johnson now expects between 8.95 dollars and 9.10 dollars for 2020, with adjusted operational sales growth of between 5% and 6%.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
4% at 5.03 billion dollars, i.e. 1.88 dollar per share, while the street expected one cent less.
The healthcare group's revenues increased by 1.7% to over 20.7 billion dollars, up 2.6% in operational terms (i.e. excluding FX factors). When also adjusted for changes in the group's consolidation scope, revenues increased by 3.4%.
With FY adjusted EPS of 8.68 dollars, against a target range of between 8.84 dollars and 8.89 dollars, provided three months ago, Johnson & Johnson now expects between 8.95 dollars and 9.10 dollars for 2020, with adjusted operational sales growth of between 5% and 6%.
Copyright (c) 2020 CercleFinance.com. All rights reserved.